Jpmorgan Chase & CO Pro Qr Therapeutics N.V. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 314 shares of PRQR stock, worth $1,139. This represents 0.0% of its overall portfolio holdings.

Number of Shares

314

Previous 1,493 78.97%

Holding current value

$1,139

Previous $3,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.65 - $2.39 $1,945 - $2,817	-1,179 Reduced 78.97%	314 $0
Q1 2024 May 10, 2024	SELL	$1.89 - $2.85 $606 - $914	-321 Reduced 17.7%	1,493 $3,000
Q4 2023 Feb 12, 2024	SELL	$1.15 - $2.21 $167,544 - $321,977	-145,691 Reduced 98.77%	1,814 $3,000
Q3 2023 Nov 14, 2023	SELL	$1.3 - $1.77 $42,759 - $58,218	-32,892 Reduced 18.23%	147,505 $191,000
Q2 2023 Aug 11, 2023	SELL	$1.62 - $2.32 $68,329 - $97,855	-42,179 Reduced 18.95%	180,397 $292,000
Q1 2023 May 11, 2023	BUY	$1.99 - $3.66 $439,348 - $808,047	220,778 Added 12279.09%	222,576 $474,000
Q4 2022 Feb 13, 2023	SELL	$0.8 - $3.7 $2,426 - $11,222	-3,033 Reduced 62.78%	1,798 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $0.89 $710,313 - $854,295	-959,883 Reduced 99.5%	4,831 $4,000
Q2 2022 Aug 11, 2022	SELL	$0.56 - $1.0 $7,324 - $13,080	-13,080 Reduced 1.34%	964,714 $750,000
Q1 2022 May 11, 2022	BUY	$0.9 - $8.39 $241,483 - $2.25 Million	268,315 Added 37.82%	977,794 $885,000
Q4 2021 Feb 10, 2022	SELL	$6.58 - $8.44 $1.59 Million - $2.04 Million	-241,581 Reduced 25.4%	709,479 $5.68 Million
Q3 2021 Nov 12, 2021	BUY	$5.16 - $8.47 $4.91 Million - $8.06 Million	951,060 New	951,060 $7.96 Million

Others Institutions Holding PRQR

# of Institutions

Shares Held

17.3M

Call Options Held

26.2K

Put Options Held

8.6K

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $259M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Pro Qr Therapeutics N.V. Transaction History